Epoxycyclohexenone inhibits Fas-mediated apoptosis by blocking activation of pro-caspase-8 in the death-inducing signaling complex.
Death receptors belong to the tumor necrosis factor receptor family. They can induce apoptosis following engagement with specific ligands and are known to play an important role in the regulation of the immune system. Here we report that epoxycyclohexenone (ECH) inhibits apoptosis induced by anti-Fas antibody, Fas ligand (FasL), or tumor necrosis factor-alpha but not by staurosporine, MG-132, C2-ceramide, or UV irradiation. These results suggest that ECH specifically blocks death receptor-mediated apoptosis. Neither the surface expression of Fas nor the Fas-FasL interaction was influenced by ECH. However, ECH did block the activation of pro-caspase-8 in the death-inducing signaling complex, although recruitment of Fas-associating death domain (FADD) and pro-caspase-8 was not affected. ECH inhibited the enzymatic activity of recombinant active caspase-8 at slightly lower concentrations than it did for active caspase-3 and active caspase-9 in vitro. However, in FasL-treated cells, ECH was only able to inhibit the activation of pro-caspase-8, and it had no effect on the already activated caspase-8 at a concentration that is effective at inhibiting Fas-induced apoptosis. ECH directly bound the large subunit of active caspase-8 that contains the active center cysteine and had a relatively higher affinity to pro-caspase-8. Moreover, compared with pro-caspase-3 and pro-caspase-9, pro-caspase-8 was predominantly depleted by biotinylated ECH with avidin beads in the cell lysates, suggesting that ECH preferentially affects pro-caspase-8. Thus, our results suggest that ECH blocks the self-activation of pro-caspase-8 in the death-inducing signaling complex and thus selectively inhibits death receptor-mediated apoptosis.
Miyake
Yasunobu
Y
Antibiotics Laboratory, Discovery Research Institute, RIKEN, Wako-shi, Saitama 351-0198, Japan.
Kakeya
Hideaki
H
Kataoka
Takao
T
Osada
Hiroyuki
H
D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D001483:Base Sequence; D053181:Caspase 8; D053453:Caspase 9; D020169:Caspases / Q000378:metabolism*; D003512:Cyclohexanones / Q000494:pharmacology*; D017931:DNA Primers; D004789:Enzyme Activation / Q000187:drug effects*; D004792:Enzyme Precursors / Q000378:metabolism*; D005434:Flow Cytometry; D006801:Humans; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D019014:fas Receptor / Q000502:physiology*
D003512:Cyclohexanones; D017931:DNA Primers; D004792:Enzyme Precursors; D018124:Receptors, Tumor Necrosis Factor; D019014:fas Receptor; C036468:cyclohexanone; C505530:CASP8 protein, human; C506433:CASP9 protein, human; D053181:Caspase 8; D053453:Caspase 9; D020169:Caspases